Objective Gastro-esophageal reflux disease (GERD) is a common medical problem with a broad spectrum of symptoms and varying degrees of severity and frequency. Most patients with GERD, regardless of endoscopic status, suffer symptomatic relapses within few months from stopping acid suppressant therapy, thus requiring long term management of their disease to prevent relapses. On-demand therapy (i.e., medication taken as needed to relieve symptoms) might be an effective modality of long-term treatment in patients with non-erosive gastro-esophageal reflux disease. An economic evaluation, the ONE (ON-demand treatment with Esomeprazole) study, was conducted to assess costs and consequences over a 6-month period with the 20 mg esomeprazole on-demand strategy compared to the 20 mg once daily continuous therapy in patients with GERD.